Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.
References
1.
ZumlaA., HuiD.S., PerlmanS.Middle East respiratory syndrome.Lancet2015; 386: 995–1007.
2.
FalzaranoD., de WitE., RasmussenA.L.Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.Nat Med2013; 19: 1313–1317.
3.
FalzaranoD., de WitE., MartellaroC.Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.Sci Rep2013; 3: 1686.
4.
OmraniA.S., SaadM.M., BaigK.Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.Lancet Infect Dis2014; 14: 1090–1095.
5.
ShalhoubS., FarahatF., Al-JiffriA.IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.J Antimicrob Chemother2015; 70: 2129–2132.
6.
Al-TawfqJ.A., MomattinH., DibJ., MemishZ.A.Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.Int J Infect Dis2014; 20: 42–46.
7.
ChuC.M., ChengV.C., HungI.F.Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.Thorax2004; 59: 252–256.
8.
de WildeA.H., JochmansD., PosthumaC.C.Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.Antimicrob Agents Chemother2014; 58: 4875–4884.
9.
SpanakisN., TsiodrasS., HaagmansB.L.Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.Int J Antimicrob Agents2014; 44: 528–532.
10.
MemishZ.A., Al-TawfqJ.A., MakhdoomH.Q.Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome.J Infect Dis2014; 210: 1590–1594.
11.
GueryB., PoissyJ., el MansoufL.Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission.Lancet2013; 381: 2265–2272.
12.
ChanJ.F., ChanK.H., KaoR.Y.Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.J Infect2013; 67: 606–616.
13.
Mair-JenkinsJ., Saavedra-CamposM., BaillieJ.K.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.J Infect Dis2015; 211: 80–90.
14.
CortiD., ZhaoJ., PedottiM.Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.Proc Natl Acad Sci U S A2015; 112: 10473–10478.
MomattinH., MohammedK., ZumlaA.Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy.Int J Infect Dis2013; 17: e792–e798.
